Helen Whitford
Overview
Explore the profile of Helen Whitford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barnes H, Niewodowski D, Doi A, Marasco S, Joseph T, Siemienowicz M, et al.
Intern Med J
. 2024 Aug;
54(10):1616-1625.
PMID: 39087843
Chronic thromboembolic pulmonary disease (CTEPD) with or without pulmonary hypertension (PH) is an important potential consequence of venous thromboembolic disease. Untreated CTEPD with pulmonary hypertension (CTEPH) is associated with high...
2.
Skoro-Sajer N, Sheares K, Forfia P, Heresi G, Jevnikar M, Kopec G, et al.
Pulm Circ
. 2024 Jul;
14(2):e12406.
PMID: 38947169
Advances in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) over the past decade changed the disease landscape, yet global insight on clinical practices remains limited. The CTEPH global cross-sectional...
3.
Kopec G, Forfia P, Abe K, Beaudet A, Gressin V, Jevnikar M, et al.
Pulm Circ
. 2024 Feb;
14(1):e12330.
PMID: 38384932
Early recognition and diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) is crucial for improving prognosis and reducing the disease burden. Established clinical practice guidelines describe interventions for the diagnosis and...
4.
Kearney K, Brown K, Celermajer D, Collins N, Cordina R, Corrigan C, et al.
Chest
. 2023 Nov;
165(4):967-977.
PMID: 37951349
Background: Current guidelines recommend initial monotherapy for pulmonary arterial hypertension (PAH) with cardiopulmonary comorbidities, despite limited available evidence to guide management. Research Question: Do left heart disease (LHD) risk factors...
5.
Chandrasekara S, Lau E, Anderson J, Collins N, Cordina R, Corrigan C, et al.
Heart Lung Circ
. 2022 Dec;
32(2):156-165.
PMID: 36503731
Background: Pulmonary arterial hypertension (PAH) has a progressive, unremitting clinical course. Vasoreactivity testing (VdT) during right heart catheterisation (RHC) identifies a subgroup with excellent long-term response to calcium channel blockade...
6.
Otto M, McGiffin D, Whitford H, Kure C, Snell G, Diehl A, et al.
J Crit Care
. 2022 Aug;
72:154120.
PMID: 35914371
Purpose: Bilateral lung transplantation for end-stage pulmonary arterial hypertension (PAH) is traditionally associated with higher early post-transplant mortality when compared with other indications. Changes in perioperative management, including the growing...
7.
Clements W, Venn G, McGiffin D, Moriarty H, Joseph T, Goh G, et al.
Respir Med
. 2022 Mar;
195:106784.
PMID: 35232634
Introduction: In many patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH), bronchial artery hypertrophy is observed. Patients with bronchial dilatation have been shown to be at increased risk of hemoptysis introducing...
8.
Doi A, Gajera J, Niewodowski D, Gangahanumaiah S, Whitford H, Snell G, et al.
J Card Surg
. 2022 Jan;
37(4):1019-1025.
PMID: 35040512
Background And Aim: Giant aneurysm of the pulmonary artery (PAA) is an extremely rare condition that may develop in patients with pulmonary arterial hypertension (PAH) which may be complicated by...
9.
Kearney K, Gold J, Corrigan C, Dhital K, Boshell D, Haydock D, et al.
Respirology
. 2021 Oct;
26(12):1171-1180.
PMID: 34608706
Background And Objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition occurring in 2%-4% of patients after acute pulmonary embolism. Pulmonary endarterectomy (PEA) is a potential cure for technically...
10.
Kennedy J, Walker A, Ellender C, Steinfort K, Martin C, Smith C, et al.
Intern Med J
. 2021 Mar;
52(6):995-1001.
PMID: 33656222
Background: Lung transplantation is a recognised treatment for end-stage lung disease due to bronchiectasis. Non-cystic fibrosis (CF) bronchiectasis and CF are often combined into one cohort; however, outcomes for non-CF...